美国医疗科技企业纽威利斯近日取得血液过滤系统核心设计及相关方法的发明专利。该项专利技术通过纳入置换液与滤出液密度参数，显著提升了液体平衡计算的精确度。
目前多数连续肾脏替代疗法（CRRT）系统采用预设液体密度参数，但实际临床中液体密度存在波动。公司声明指出，若未进行密度校准，将导致具有临床意义的液体平衡误差。
纽威利斯的创新解决方案使系统可通过三种途径实现密度校准：用户手动输入、设备自动测量或数据推导计算。这种动态密度补偿机制大幅提升了液体容积流量追踪的精准度，为危重症患者的血液净化治疗提供了更可靠的技术保障。
（本文根据美国专利商标局公开信息及企业公告撰写）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.